Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease

Haematologica

Volumn 99, Issue 10, 2014, Pages 1618-1623

  Inamoto, Yoshihiro ^a   Martin, Paul J ^a   Storer, Barry E ^a   Palmer, Jeanne ^b   Weisdorf, Daniel J ^c   Pidala, Joseph ^d   Flowers, Mary E D ^a   Arora, Mukta ^c   Jagasia, Madan ^e   Arai, Sally ^f   Chai, Xiaoyu ^a   Pavletic, Steven Z ^g   Vogelsang, Georgia B ^h   Lee, Stephanie J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TRACT; HUMAN; LIVER; LONGITUDINAL STUDY; LUNG; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK; SCORING SYSTEM; SKIN; ADVERSE EFFECTS; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84907479622     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109611     Document Type: Article

References (25)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-33.
2. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-Tcell globulin ATG-Fresenius. Blood. 2011;117(23):6375-82.
3. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304(25):1529-33.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-62.
5. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767-76.
6. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11):1852-8.
7. Inamoto Y, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118(2):456-63.
8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
9. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graftversus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-14.
10. Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the National Institutes Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008; 14(10):1163-71.
11. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78-84.
12. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-9.
13. Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26(4):746-56.
14. Chronic GVHD Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant. 2011;17(8):1114-20.
15. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74(4):1428-35.
16. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-8.
17. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714-20.
18. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-23.
19. Singer JD, Willett JB. Describing Continuous-time Event Occurrence Data. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press, 2003:468.
20. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient reported skin score and outcome: results from the Chronic GVHD Consortium. Blood. 2012;120(13):2545-52.
21. Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers ME, Palmer J, et al. Analysis of gastrointestinal and hepatic chronic graft-versus-host disease manifestations on major outcomes: a Chronic Grant-Versus-Host Disease Consortium study. Biol Blood Marrow Transplant. 2013;19(5):784-91.
22. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med. 1989;111(5):368-76.
23. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graftversus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657-66.
24. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol. 2012;49(1): 15-24.
25. Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47(11):1470-3.